Status:
COMPLETED
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis B, Chronic
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This study will evaluate the efficacy and safety of PEGASYS (peginterferon alfa-2a) in patients with HBeAg positive chronic hepatitis B. Patients will be stratified into group A (treatment naïve patie...
Eligibility Criteria
Inclusion
- Adult patients, 18-65 years of age
- HBsAg +ve for more than 6 months, HBeAg +ve, AntiHBs -ve
- Detectable hepatitis B virus (HBV) DNA (\>100,000 copies/mL)
Exclusion
- Coinfection with hepatitis A, hepatitis C or human immunodeficiency virus (HIV)
- Evidence of decompensated liver disease
- A medical condition associated with chronic liver disease other than viral hepatitis
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01519921
Start Date
October 1 2005
End Date
June 1 2008
Last Update
April 21 2016
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Busan, South Korea, 49241
2
Daegu, South Korea, 41944
3
Seoul, South Korea, 03722
4
Seoul, South Korea, 05505